Astellas To Pay $7M To End Mycamine FCA Suit
Astellas Pharma US Inc. has agreed to pay $7.3 million to settle a whistleblower False Claims Act suit from a former sales representative alleging that it marketed antifungal treatment Mycamine off-label...To view the full article, register now.
Already a subscriber? Click here to view full article